INTRODUCTION
Arachidonic acid (AA) can be metabolised by a number of different enzyme systems including cyclooxygenase, lipoxygensase and the cytochrome P450 to a range of bioactive metabolites.
Enzymes of CYP4A, 4B and 4F families catalyse -hydroxylation of fatty acids. Several isoforms produce 20-hydroxyeicosatetraenoic acid (20-HETE) when incubated with arachidonic acid. There is accumulating evidence that 20-HETE is involved in the pathogenesis of hypertension [1] . 20-HETE is a vasoconstrictor but also inhibits renal sodium reabsorption causing a natriuresis [2] . Therefore the effect of 20-HETE on blood pressure can be complicated and dependent on the site of synthesis. The efficacy of interventions to lower blood pressure varies significantly between individuals and is partly determined by genetic background.
The CYP4F2 and CYP4A11 enzymes function as renal 20-HETE synthases in humans [3, 4] .
In human renal microsomes the CYP4F2 isoform accounts for ~70% of the 20-HETE production [3] . A guanine to-adenine missense transition at nucleotide (nt) 1347 on the CYP4F2 gene results in a nonsynonymous valine-to-methionine amino acid substitution at residue 433. In an in vitro study transfection of this single nucleotide polymorphism into Sf9 insect cells using recombinant baculoviruses resulted in a 50% reduction in 20-HETE production [3] . A functional polymorphism has also been described for CYP4A11 gene. The polymorphism is a thymidine-to-cytosine missense transition at nucleotide 8590 that results in a nonsynonymous phenylalanine-to-serine amino acid substitution at residue 434. This substitution has little effect on the enzyme's affinity for arachidonic acid but does reduce the enzymatic activity by ~50% in vitro and has been associated with hypertension in a white, but not African American, population [4] . 4 These two common functional polymorphisms CYP4A11 T8590C (also referred to as CYP4A11 F434S) and the CYP4F2 G1347A (CYP4F2 V433M) have been associated with increased blood pressure in population studies and have been postulated to act by altering 20-HETE levels [3, 5] . In a study of more than 200 normotensive and hypertensive men and women, we showed that the A allele of the CYP4F2 G1347A polymorphism was associated with increased urinary 20-HETE excretion and elevated systolic blood pressure while the Callele of the CYP4A11 T5890C polymorphism was associated with reduced urinary 20-HETE.
We have previously shown that overweight subjects with features of the metabolic syndrome had higher plasma and urinary 20-HETE excretion compared with their case controls [6] . This study examined the effect of the G1347A polymorphism of CYP4F2 on blood pressure and plasma and urinary 20-HETE in response to weight loss in overweight men and women.
Although the CYP4A11 5890 T/C polymorphism has been associated with elevated blood pressure, we observed that the C-allele for the CYP4A11 5890 T/C had opposing effects on urinary 20-HETE compared with the A-allele for CYP4F2 1347 G/A. For this reason C-allele carriers of the CYP4A11 5890 T/C polymorphism were excluded from the study. We hypothesised that a similar degree of weight loss in carriers of the G1347A polymorphism of CYP4F2 would result in a greater fall in blood pressure and urinary 20-HETE than non-carriers.
STUDY DESIGN AND METHODS

Participant Recruitment
Men aged between 20 and 70 years and post-menopausal women less than 70 years were recruited from the general population by newspaper advertisement. They were telephone screened and invited to attend our research unit for further screening if they reported being overweight, had no known chronic diseases and were not taking medication for hypertension or lipid disorders.
Screening
At the first screening visit height, weight and waist circumference were measured. Volunteers completed a lifestyle questionnaire, which included details of medical history, any medication usage and alcohol consumption. A fasting blood sample was obtained for measurement of glucose, lipids (total cholesterol, HDL cholesterol, triglycerides and derived LDL cholesterol) creatinine and liver function. Blood pressure was measured in the seated position using a Dinamap 1846 SX P (Critikon; USA). Six BP readings were obtained at 1 min intervals, after 5min seated rest, on 2 separate days. Participants completed 3-day diet records to estimate their caloric intake. Volunteers whose waist circumference fitted the criteria of the metabolic syndrome according to the National Cholesterol Education Program Adult Treatment Panel III [7] , >102cm for men and >88cm for women, and whose SBP was >120 mmHg were referred for a physical examination to ensure they qualified for the study. The volunteers were then screened for the CYP4F2 G1347A and CYP4A11 T8590C polymorphisms prior to being studied.
Exclusion Criteria
Volunteers were further excluded if they were smokers, carriers of the C-allele for the CYP4A11 T8590C polymorphism, consuming > 30g alcohol/day or > 40g alcohol in a single session, or if they had a history of cardiovascular or peripheral vascular disease, diabetes, renal disease or liver disease.
The study was approved by the University of Western Australia Human Ethics Committee and volunteers provided written informed consent to participate. The weight loss intervention was registered with the Australian Clinical Trials Registry # ACTRN12610000714088.
Weight reduction intervention
Two groups were studied in parallel:-those genotyped as carrying the A-allele (GA/AA) for the CYP4F2 G1347A polymorphism and those homozygous for the G-allele (GG, wildtype) who acted as controls. Both groups participated in a 16 week study. The first 12 weeks was a weight loss program followed by a 4 week program designed to stabilise weight. After baseline measurements, all volunteers received individualised diet counselling every two weeks that aimed to restrict calories by ~2000-6500 kJ/day (depending on baseline caloric intake), leading to a reduction in weight of ~4-5kg. This was followed by 4 weeks of counselling with a view to stabilising weight. All participants were instructed not to change their level of physical activity or alcohol consumption during the study and completed a questionnaire at baseline, 12 and 16 weeks relating to their level of physical activity and alcohol consumption. At baseline, 12 and 16 weeks, all participants had BP monitored for 24hr, weight and waist circumference was measured, and they provided a fasting blood sample and 24hr urine collection. A threeday diet record was completed at baseline and during week 12 and week 16 and the major nutrients were examined overtime using Foodworks.
Measurements
Ambulatory BP Monitoring
Ambulatory BP was monitored for 24hr with a Spacelabs 90207 monitor (Spacelabs Healthcare, Issaquah, WA, USA) set to record at 20-minute intervals while awake and 30-minute intervals while asleep. The monitor was fitted to the non-dominant arm by a trained researcher. The correct cuff size was determined by measuring mid-arm circumference.
Volunteers were instructed to continue their normal routine and maintain a diary while awake.
A valid 24hr recording was accepted as a minimum of 80% successful readings. Aggregated readings for each hour, were used to determine average 24hr SBP, DBP and MAP. Awake and asleep periods were determined from the subject's diary.
Blood collection and biochemical measurements
A fasted venous blood sample was collected into cold tubes containing EDTA and reduced glutathione and centrifuged immediately at 1000 x g for 10 min at 
Urinary and plasma 20-HETE
Urinary 20-HETE was measured by gas chromatography mass spectrometry (GCMS) using electron capture negative chemical ionization. The assay was a modification of the method previously described [8] as previously described for urine [8] .
STATISTICAL ANALYSIS
The study was powered on the basis of using a dominant-effect model for the CYP4F2 G1347A polymorphism as previously described [5] . This model compares the combined effect of the CYP4F2 AA/GA genotypes with the CYP4F2 GG (wildtype genotype). From our previous studies, we estimated that if we excluded carriers of the C-allele for the CYP4A11 T8590C
polymorphism and compared 21 volunteers genotyped CYP4F AA/GA with 21 volunteers genotyped CYP4F2 GG , we would have 80% power to detect a 20% difference in urinary 20-HETE and plasma 20-HETE at P<0.05.
All analysis used the STATA 12 statistical package. Blood pressure and heart rate analysis used the average hourly readings at baseline, 12 and 16 weeks. Pulse pressure (SBP-DBP) was calculated from the hourly readings at baseline, 12 and 16 weeks. Between genotype 9 differences in SBP, DBP heart rate and pulse pressure; urinary 20-HETE, body weight, lipids and glucose were compared over time using linear mixed models with restricted maximum likelihood estimation that adjusts for differences at baseline and the effect of time. The influence of the CYP4F2 allele status over time was assessed by incorporating interaction terms for the effect of allele status and time for each outcome variable. Linearity assumptions were assessed using restricted cubic splines. A p value less than 0.05 was regarded as statistically significant. The models were adjusted for the effects of gender, dietary sodium and potassium intake as assessed from urine collection and major dietary components assessed from 3-day diet records.
RESULTS
Four hundred and nineteen men and women were telephone screened, 137 underwent screening at the research unit that included measurement of anthropometry, blood pressure, biochemistry and genotyping. Fifty-seven were suitable for study but 4 declined to participate. Fifty-three volunteers entered the study. Twenty six were carriers of the A-allele of the CYP4F2 G1347A polymorphism and 27 were homozygous for the G-allele. Forty-two completed the study with equal numbers in each group. Baseline characteristics for the two genotypes are described in Table 1 . There were 21 volunteers who were heterozygotes (GA) and 5 who were homozygous (AA) for the A-allele of the CYP4F2 G1347A polymorphism. At baseline, the two groups were similar with respect to age, gender distribution, BMI, waist circumference, fasting glucose total and HDL cholesterol. Triglycerides were higher in the A-allele carriers.
The rate of weight loss was similar between the GG genotype and A-allele carriers ( Figure 1 ).
Compared with baseline, body weight was reduced by -3.9 kg (CI -6. Table 2 .
Major dietary components (total fat, protein and carbohydrate) assessed from 3-day diet records
were not different between the genotypes over time.
The effect of CYP4F2 genotype on 24 hour blood pressure and heart rate and pulse pressure responses to weight loss
The mean 24 hour, awake, and asleep SBP and DBP at baseline, 12weeks and 16 weeks are shown in Table 2 . Figure 2 (A-C) shows the unadjusted hourly SBP in A-allele carriers compared with the GG genotype at baseline (Figure 2A ), and after 12 weeks ( Figure 2B ) and 16 weeks ( Figure 2C ). At baseline, the A-allele carriers had 24 hour ambulatory SBP that was on average higher +1.7mmHg (CI 0.1, 3.35 mmHg, P =0.047) compared with the GG genotype (Table 3) . When the data was analysed according to whether the volunteers were awake or asleep SBP in the A-allele carriers tended to be higher at baseline but not significantly so during both awake and asleep periods ( Table 2) . SBP fell in response to weight reduction by an average of -7.6mmHg, (CI -12.4,-2.7 mmHg, P=0.004), and was not different between the two groups after 12 weeks (P=0.383) ( Table 3 ). Awake and asleep SBP at 12 weeks are shown in Figure 2D ), and after 12 weeks ( Figure 2E ) and 16 weeks ( Figure 2F ).
At baseline, the A-allele carriers average 24 hour DBP was lower -1.4 mmHg (CI -2.6, -0.3mmHg, P=0.014) than the GG genotype ( Table 3 ). The difference in 24hr DBP was mainly due to lower DBP in the A-allele carriers during awake hours (P<0.05) with little difference between the genotypes observed while asleep ( Table 2) . Compared with baseline, DBP fell to a similar extent in both groups after 12 weeks of weight reduction -5.4mmHg (CI -9.4, -1.4 mmHg, P=0.008) and was not different between the groups (Table 2 ). Awake and asleep DBP at 12 weeks are shown in Table 2 . The A-allele carriers had significantly higher DBP after weight stabilisation +3.2mmHg (CI 1.6, 5.0 mmHg, P=0.0001) compared with the GG genotype ( Table 3 ). The rebound increase in DBP in A-allele carriers was mainly due to a rebound in DBP during awake hours (P<0.05).
Heart rate was lower in the A-allele carriers at baseline -1.8beats/min, (CI -2.9, -0.7 beats/min,
P=0.0001).
Heart rate fell in to the same extent in both groups with weight reduction -5.4beats/min, (CI -9.0, -1.8 beats/min, P=0.004) and was not different between the groups (Table 3) . After weight stabilisation heart rate in the A-allele carriers was significantly elevated compared with the GG genotype +2.6 beats/min, (CI 0.9, 4.3 beats/min, P=0.0001) ( Table 3 ).
The differential effect of the A-allele to increase SBP, DBP and heart rate after weight stabilisation was not affected by changes in weight, sodium excretion, fasting glucose or differences in nutrient intake.
Pulse pressure was significantly higher in the A-allele carriers +3.1mmHg, (CI 2.3, 3.8mmHg, P=0.0001) ( Table 3) . Compared with baseline, there was a fall in pulse pressure after 12 weeks weight loss -2.5mmHg (-3.6,-1.4 mmHg, P=0.0001) and at 16 weeks -2.0mmHg (CI -3.1,-0.9 mmHg, P=0.0001) that was similar for both genotypes ( Table 3 ).
The effect of CYP4F2 genotype on urinary 20-HETE in response to weight loss.
Urinary 20-HETE was not different between the genotypes at baseline and was not significantly different after 12 weeks weight loss. However, the response to weight maintenance differed between the two genotypes with the A-allele carriers having significantly higher urinary 20-HETE compared with the GG genotype after weight maintenance P=0.017 (Table 4 ). The genotype differences in urinary 20-HETE during weight maintenance were still significant (P=0.012) after adjusting for changes in sodium intake as assessed from 24h sodium excretion 
The effect of CYP4F2 genotype on glucose and blood lipids in response to weight loss
In regression models that included the effect of genotype and time, there was no significant difference between the genotypes with respect to fasting levels of glucose, cholesterol, or HDL cholesterol at any time point (Table 5 ). All of these parameters fell significantly in both groups 13 with weight reduction and remained lower at 16 weeks. Triglycerides levels were significantly higher (+0.28±0.12mmol/L, P=0.021) in A-allele carriers at all time-points Triglycerides levels were reduced to a similar extent in both groups with weight reduction and remained lower at 16 weeks (Table 5) . Our baseline data in overweight volunteers confirm previous reports of higher SBP in carriers of the polymorphism [5, 9] . In contrast, baseline DBP was comparatively lower in the A-allele carriers. The fall in SBP and DBP in response to weight reduction was similar between the genotypes, and the rebound increase in blood pressure in A-allele carriers after weight maintenance could not be explained by genotype differences in weight, glucose, sodium or nutrient intake. The mechanism related to the increase in blood pressure is unknown. However, differences in plasma renin activity, muscle sympathetic nerve activity and baroreflex sensitivity have been described in humans during active weight loss compared with weight 14 maintenance following weight loss. A small study in humans showed that weight loss of ~10kg resulted in reduced noradrenaline spillover rate, muscle sympathetic nerve activity and plasma renin activity, and increased baroreflex sensitivity while weight maintenance associated with a rebound increase in plasma renin activity, muscle sympathetic nerve activity with reduced baroreflex sensitivity [10] . Although these parameters were not measured in our study it is possible that A-allele carriers may be particularly sensitised to these mechanisms during weight maintenance with a resultant increase in blood pressure.
DISCUSSION
Heart rate changes in the two groups after weight reduction and weight maintenance paralleled that in systolic blood pressure suggesting an autonomic adrenaline mediated or cardiac effect.
We found that A-allele carriers had significantly elevated pulse pressure compared to the GG genotype over the 16 weeks. An increased pulse pressure associates with stiffer arteries and has been reported to confer an increased risk for cardiovascular mortality and stroke [11, 12] .
Our findings agree with the report by Hu et al. who showed that carriers of this polymorphism had elevated peripheral and central augmentation index and urinary 20-HETE [13] . The fall in pulse pressure with weight loss in our study, was similar for both genotypes and in accord with reports of improvements in arterial stiffness after weight loss [14] [15] [16] . However, the fact that A-allele carriers still had higher pulse pressure may be of relevance to the increase in blood pressure after weight maintenance. In this regard, a recent study in a mouse model of diet induced obesity demonstrated that arterial stiffening preceded the development of hypertension [17] . In that study, arterial stiffening was associated with increased oxidative stress and reduced nitric oxide bioavailability both of which have been linked to increased 20-HETE synthesis [6, 18] . Therefore, it is possible that the consistently higher pulse pressure in A-allele carriers in our study may cause undue stress on the resistance vessels that manifests as 15 increased BP during weight maintenance. The precise mechanism by which BP is increased is not known but could relate to increased 20-HETE that has been associated with reduced nitric oxide and increased oxidative stress.
This study found a significant increase in urinary 20-HETE in A-allele carriers after weight stabilisation that coincided with the increase in BP. Altered urinary 20-HETE excretion may be relevant to regulation of renal function, vascular tone and BP control. Plasma 20-HETE responses were not affected by genotype suggesting that altered synthesis of 20-HETE may be confined to the kidney. In humans, the CYP4F2 isoform accounts for a large proportion of 20-HETE synthesis in the kidney [19, 20] . 20-HETE is excreted in the urine as the glucuronide conjugate [21] and may reflect renal synthesis although the site of glucuronidation is not known. 20-HETE can affect blood pressure differently depending on whether it is synthesised in the pre-glomerular vasculature where it causes vasoconstriction [22] or in the renal tubules where it causes a natriuresis [23] . There were no differential effects of the A-allele on sodium excretion after weight stabilisation. Therefore any effect of renal 20-HETE to raise blood pressure during weight stabilisation would likely be due to effects on the vasculature that may occur via multiple mechanisms including increased PRA and/or renal sympathetic nerve activity that are potent stimuli for 20-HETE synthesis [24, 25] and/or reduced nitric oxide availability [26] .
There are numerous polymorphisms of CYP4F and CYP4A genes and both CYP4F2 G1347A
and CYP4A11 T8590C polymorphisms have been associated with elevated blood pressure. We previously showed that the CYP4F2 G1347A polymorphism and CYP4A11 T8590C polymorphisms had opposite effects on urinary 20-HETE excretion [5] . Our study did not confirm our previous report of elevated 20-HETE excretion in carriers of the A allele. This may be because the population was overweight with the majority of volunteers postmenopausal women and therefore less heterogeneous in terms of BMI and gender, that have been shown to be strong predictors of urinary 20-HETE [5, 18] .
Interestingly confining our study population to exclude the effects of the CYP4A11 T8590C polymorphism also showed that carriers of CYP4F2 G1347A polymorphism had raised triglyceride levels compared with the GG genotype. A large Swedish population study also reported increased triglycerides in male but not female carriers of this polymorphism, however, that study did not exclude carriers of CYP4A11 T8590C polymorphism [27] . In our study, triglyceride responses to weight reduction and weight stabilisation were similar between the genotypes. Cholesterol, HDL cholesterol, and glucose did not differ between the genotypes and were reduced to a similar extent by weight reduction.
In conclusion, our study showed that overweight volunteers who were carriers of the A-allele for the CYP4F2 G1347A polymorphism had higher SBP, pulse pressure and triglycerides. They also have more difficulty maintaining a lower blood pressure during weight stabilisation after weight loss. This may be related to genotype differences in arterial stiffness and increased 20-HETE synthesis during weight stabilisation.
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